Quarterly ResultMay 15, 2026, 04:39 PM
NRX Pharma Q1 Net Loss Narrows to $1.4M; Going Concern Doubt
AI Summary
NRX Pharmaceuticals reported a net loss of $1.4 million for the first quarter of 2026, a significant improvement from the $5.5 million loss in the prior year. The company generated its first patient service revenue of $1.1 million, primarily through its HOPE Therapeutics subsidiary's clinical operations. Despite this, NRX Pharmaceuticals continues to face substantial doubt about its ability to continue as a going concern, with $6.7 million in cash and a working capital deficit of $17.8 million as of March 31, 2026.
Key Highlights
- Net loss for Q1 2026 narrowed to $1.4 million, compared to $5.5 million in Q1 2025.
- Generated initial patient service revenue of $1.1 million in Q1 2026, up from $0 in Q1 2025.
- Cash and cash equivalents stood at $6.7 million as of March 31, 2026, down from $7.8 million at year-end 2025.
- Reported a working capital deficit of $17.8 million as of March 31, 2026.
- Net cash used in operating activities increased to $4.3 million in Q1 2026 from $3.5 million in Q1 2025.
- Shareholders' deficit improved to $13.8 million from $15.9 million at December 31, 2025.
- Company raised $3.4 million through an At-the-Market (ATM) offering in Q1 2026.
- Management concluded substantial doubt exists regarding the company's ability to continue as a going concern.
Price Impact
More from NRXP